The purpose of this trial is to explore mifepristone as an option for induction of labor at
term by evaluating the efficacy of mifepristone use for cervical preparation. Since the Labor
Induction versus Expectant Management in Low-Risk Nulliparous Women (ARRIVE) trial supporting
that elective induction after 39 weeks decreases cesarean sections and morbidity, rates of
elective term inductions are increasing (Grobman et al. 2018).
At Lucile Packard Children's Hospital at Stanford University specifically, approximately 40%
of spontaneous vaginal deliveries follow induction of labor, with an average induction time
of 20 hours. Previous studies have established the maternal and neonatal safety of
mifepristone in term inductions, however, this study will assess the difference in overall
time from induction to complete cervical dilation, delivery, and the total time on Labor and
Delivery.